Concepedia

Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach

Debomita Bhattacharya, Alice Shi Ming Li, Barnali Paul, Uddipta Ghosh Dastidar, Vijayaratnam Santhakumar, Dipika Sarkar, Irene Chau, Fengling Li, Trisha Ghosh, Masoud Vedadi,

European Journal of Medicinal Chemistry · 2023 · 13 citations · 31 references

DOIFull text

Open access

Concepts

References

31

Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm

Guosheng Wu, D. H. Robertson, Charles L. Brooks et al. · Journal of Computational Chemistry · 2003 · 1.6K citations

, , +16

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists

B. Evans, Kenneth E. Rittle, Mark G. Bock et al. · Journal of Medicinal Chemistry · 1988 · 1.4K citations · Full text

, , +13

Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss

Andrew Fedoriw, Satyajit Rajapurkar, Shane W. O’Brien et al. · Cancer Cell · 2019 · 347 citations · Full text

, , +7

Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers

Masanori Yoshimatsu, Gouji Toyokawa, Shinya Hayami et al. · International Journal of Cancer · 2010 · 317 citations · Full text

, , +14

A chemical biology toolbox to study protein methyltransferases and epigenetic signaling

Sebastian Scheer, Suzanne Ackloo, Tiago da Silva Medina et al. · Nature Communications · 2018 · 149 citations · Full text

, , +13